



Disclosure of Relevant Financial or Non-financial/Strategic Business Relationships or Partnerships

“Current Topics in Cancer Genetics for the Breast Surgeon: Pre-testing Concerns 2025” Webinar

The Society is charged with ensuring its CME activities are balanced, independent, objective, and scientifically rigorous, through, but not limited to, by identifying and mitigating relevant financial relationships or non-financial/strategic business relationships or partnerships (relationships) between individuals in control of educational content and ineligible companies. By identifying and mitigating relevant relationships, we work together to create a protected space to learn, teach, and engage in scientific discourse free from influence from individuals that may have an incentive to insert commercial bias into a CME activity.

As a CME provider accredited by the [Accreditation Council for Continuing Medical Education \(ACCME\)](https://accme.org/rule/eligibility/), the ASBrS requires individuals in control of the educational content of a CME activity (including but not limited to, authors, content reviewers, editors, education-based committees, and ASBrS staff) to disclose all financial and non-financial/strategic business relationships or partnerships (relationships) with ACCME-defined ineligible company, within the 24 months prior to their involvement with the CME activity. An ineligible company is a company whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Please review the following examples at <https://accme.org/rule/eligibility/>.

Individuals in control of educational content must review and adhere to the ‘[ASBrS CME Activity Disclosure Policy](#)’ as well as complete the applicable ASBrS Disclosure Form at the time they are invited to participate in a CME activity. ASBrS committee members (volunteers) are also required to review and adhere to the ‘[ASBrS Volunteer Conflict of Interest Policy](#)’. Participation is not confirmed without the completion of the disclosure form and will be contingent upon mitigation, if necessary.

Owners or employees of ineligible companies are excluded from controlling content or participating as planners or faculty in a CME activity. The **owners** and **employees** of ineligible companies are considered to have unresolvable financial relationships and must be excluded from participating as planners or faculty and must not be allowed to influence or control any aspect of the planning, delivery, or evaluation of accredited continuing education.

There are three exceptions to this exclusion—owners or employees of ineligible companies can participate as planners or faculty in these specific situations:

- a. When the content of the activity is not related to the business lines or products of their employer/company.
- b. When the content of the accredited activity is limited to basic science research, such as pre-clinical research and drug discovery, or the methodologies of research, and they do not make care recommendations.
- c. When they are participating as technicians to teach the safe and proper use of medical devices, and do not recommend whether or when a device is used.

To assist all CME planners and contributors in identifying relevant relationships, ASBrS staff provides a sample list of typical relevant relationships and possible methods for mitigation –as well as examples of non-compliant actions. However, this list is not an exhaustive list of all scenarios. Participants are required to disclose all possible competing interests, both financial and non-financial, that could interfere with, or could reasonably be perceived as interfering with, their ability to provide objective and valuable contributions to the ASBrS CME activity. All identified relevant relationships are mitigated prior to the education activity being delivered to learners per ACCME Standards for Integrity and Independence in Accredited Continuing Education. The inability to mitigate an identified relevant relationship results in the participant's withdrawal from participation in the CME activity. A list of disclosures from all CME planners and contributors, as well as all potential and actual mitigation methods (including any instances of non-compliance), are documented and maintained by ASBrS staff. This list is made available to all CME activity planners.

The non-compliance process is initiated when an individual's (in control of educational content of the CME activity) *undisclosed* relationship(s) with an ineligible company is identified or reported during or after the CME activity. The Board of Directors, CME Committee, Ethics Committee, and applicable committee chair(s) will discuss the act of noncompliance and agree upon a resolution.

Oversight

In addition to the CME Committee, the Ethics Committee serves as additional oversight to further ensure there is no commercial bias or influence in ASBrS CME activities. The CME Committee and the Ethics committees work together participating in and observing ASBrS CME activities to look for evidence of bias and ensure compliance with the ASBrS policies.

Reporting Conflicts

Participants of any ASBrS CME activity may report any improprieties on the applicable evaluation form and to the CME Committee at cme@breastsurgeons.org.

Please note we have advised speakers it is their responsibility to also disclose at the start of their presentation if they will be describing the use of a device, product, or drug that is not FDA approved or the off-label use of an approved device, product, or drug or unapproved usage.

The following individuals and groups have been involved in the planning, review, implementation, approval, evaluation, and/or oversight of this activity. All disclosed relationships are within the 24 months prior to their involvement with the CME activity. All relevant disclosed relationships have been mitigated by a CME Committee Official.

Webinar Faculty

The following faculty have no relevant disclosures:

- Cory Donovan, MD (Planner, Speaker)
- Alina Mateo, MD (Speaker)
- Jennifer Plichta, MD (Planner, Speaker)
- Meagan Smith, MD (Speaker)

The following faculty members have disclosed the following relevant relationships:

- Kevin Hughes, MD (Speaker)
 - *Aptitude Health; Consultant*
 - *AstraZeneca; Speaker*
 - *Hologic; Consultant*
 - *Volpara Health, Inc.; Travel Expenses; Consultant*

Peer review of presentation was performed by the CME committee. Presentation is free of commercial bias and does not promote commercial material.

Activity Planners – Genetics Committee Chairs

The following planners have no relevant disclosures:

- Cory Donovan, MD - Vice-Chair (Planner, Speaker)
- Jennifer Plichta, MD – Chair (Planner, Speaker)

Program Approver

The following approver has relevant disclosures. Dr. Boughey recused herself from discussions and decisions where a conflict of interest could occur.

- Judy Boughey, MD (President, Board of Directors)
 - Lily; Research Support; Study PI

Reviewers, Regulatory - CME Committee Chairs

The following committee members have no relevant disclosures:

- Jillian Lloyd, MD (Vice-Chair)
- Sarah McLaughlin, MD (Chair)

Oversight - Ethics Committee

The following committee members have no relevant disclosures:

- Katherina Zabicki Calvillo MD
- Cindy Matsen, MD (Vice-Chair)
- Puneet Singh, MD
- Stephanie Serres, MD
- Jennifer Fieber, MD

The following Ethics committee members have relevant disclosures. ***All committee members recused themselves from discussions, decisions and oversight where a conflict of interest could occur.***

- Jennifer Tseng, MD
 - Intuitive Surgical; Site PI on multicenter clinical trial
- Tina Hieken, MD (Chair)
 - Genentech; Research Funding (Institution)
 - SkylineDX BV; Research Funding (Institution)
- Lisa Allen, MD
 - Elucent; Consulting Fee

ASBrS Staff

The following staff have no relevant disclosures:

- Erica J. Holland, Executive Director
- Maribeth Girard, MD, Genetics Staff Liaison
- Tekoah White, Education Manager